Arrambide Georgina, Iacobaeus Ellen, Amato Maria Pia, Derfuss Tobias, Vukusic Sandra, Hemmer Bernhard, Brundin Lou, Tintore Mar
Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Division of Neurology, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Mult Scler. 2020 Jun 12;26(9):1352458520924595. doi: 10.1177/1352458520924595.
The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
多发性硬化症(MS)的自然病程具有高度异质性。有一部分患者患有可称为侵袭性MS的疾病。这些患者可能频繁发生严重复发且恢复不完全,在疾病早期就有发展为更严重和永久性残疾的风险。他们的治疗机会窗口可能很窄,虽然一般认为他们会从早期开始使用高效治疗中获益,但目前尚无侵袭性MS的统一定义,且关于其治疗的数据也非常缺乏。基于欧洲多发性硬化症治疗与研究委员会(ECTRIMS)主办的一次国际专题研讨会上的讨论,我们回顾了目前关于侵袭性MS患者治疗的知识。我们分析了现有证据,找出知识空白,并提出填补这些空白所需的未来研究方向。一篇配套论文详述了就侵袭性MS的定义达成共识所面临的困难。